ArticlePloS one2017
Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- The number of cases, mortality and treatments of viral hemorrhagic fevers: A systematic review.PLoS neglected tropical diseases · 2022Pooled it
- Anti-Ebola therapy for patients with Ebola virus disease: a systematic review.BMC infectious diseases · 2019Pooled it
- Delayed type I interferon response and the subsequent out-of-sequence cytokine signal inhibit T cell induction in non-surviving Ebola virus-infected patients.Frontiers in immunology · 2026Article
- Article
- Asian elephant interferons alpha and beta and their anti-herpes viral activity.Frontiers in immunology · 2025Article
- Recent Advances in Therapeutic Approaches Against Ebola Virus Infection.Recent advances in anti-infective drug discovery · 2024Review
- Antiviral options and therapeutics against influenza: history, latest developments and future prospects.Frontiers in cellular and infection microbiology · 2023Review
- Article
- Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019.European journal of pharmacology · 2022Review
- Mechanisms of phosphatidylserine influence on viral production: A computational model of Ebola virus matrix protein assembly.The Journal of biological chemistry · 2022Article
- Article
- Treatment with Ad5-Porcine Interferon-α Attenuates Ebolavirus Disease in Pigs.Pathogens (Basel, Switzerland) · 2022Article
- Therapeutic Strategies against Ebola Virus Infection.Viruses · 2022Review
- ETV7 limits antiviral gene expression and control of influenza viruses.Science signaling · 2021Article
- Immunotherapeutics for Ebola Virus Disease: Hope on the Horizon.Biologics : targets & therapy · 2021Review
- Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery.Frontiers in pharmacology · 2021Review
- Interferon Beta Activity Is Modulated via Binding of Specific S100 Proteins.International journal of molecular sciences · 2020Article
- The Plasma Mobile, 'A gift from heaven': The impact of health technology transfer on trial perceptions and expectations during the Ebola-Tx Trial, Conakry.PLoS neglected tropical diseases · 2020Article
- The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19.Frontiers in immunology · 2020Review
- Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study.The Journal of infectious diseases · 2019Observational
Corrections and comments
- Erratum issued
Authors and funding
16 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date there are no approved antiviral drugs for the treatment of Ebola virus disease (EVD). Based on our in vitro evidence of antiviral activity of interferon (IFN)-ß activity against Ebola virus, we conducted a single arm clinical study in Guinea to evaluate the safety and therapeutic efficacy of IFN β-1a treatment for EVD. Nine individuals infected with Ebola virus were treated with IFN β-1a and compared retrospectively with a matched cohort of 21 infected patients receiving standardized supportive care only during the same time period at the same treatment unit. Cognizant of the limitations of having treated only 9 individuals with EVD, the data collected are cautiously considered. When compared to supportive care only, IFN β-1a treatment seemed to facilitate viral clearance from the blood and appeared associated with earlier resolution of disease symptoms. Survival, calculated from the date of consent for those in the trial and date of admission from those in the control cohort, to the date of death, was 19% for those receiving supportive care only, compared to 67% for those receiving supportive care plus IFN β-1a. Given the differences in baseline blood viremia between the control cohort and the IFN-treated cohort, an additional 17 controls were included for a subset analysis, from other treatment units in Guinea, matched with the IFN-treated patients based on age and baseline blood viremia. Subset analyses using this expanded control cohort suggests that patients without IFN β-1a treatment were ~ 1.5-1.9 fold more likely to die than those treated. Viewed altogether the results suggest a rationale for further clinical evaluation of IFN β-1a.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.